Understanding the kinomic contributions to tyrosine kinase inhibitor resistance in triple negative breast cancer

被引：0
|
作者：
Lefebvre, Cory [1 ]
Litchfield, David [1 ]
Allan, Alison [1 ]
机构：
[1] Western Univ, London, ON, Canada
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.SABCS18-1282
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1282
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Protein kinase C inhibitor chelerythrine selectively inhibits proliferation of triple-negative breast cancer cells
    Lin, Wanjun
    Huang, Jiajun
    Yuan, Zhongwen
    Feng, Senling
    Xie, Ying
    Ma, Wenzhe
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [42] Antitumoral activity of EC70124, a novel multitarget kinase inhibitor, in triple negative breast cancer.
    Cuenca-Lopez, Maria D.
    Carlos Montero, Juan
    Serrano-Heras, Gemma
    Corrales-Sanchez, Veronica
    Morales, Jorge
    Moris, Francisco
    Pandiella, Atanasio
    Ocana Fernandez, Alberto
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] ABL Tyrosine Kinase Inhibition Variable Effects on the Invasive Properties of Different Triple Negative Breast Cancer Cell Lines
    Chevalier, Clement
    Cannet, Aude
    Descamps, Simon
    Sirvent, Audrey
    Simon, Valerie
    Roche, Serge
    Benistant, Christine
    [J]. PLOS ONE, 2015, 10 (03):
  • [44] Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways
    Wu, Xinyan
    Zahari, Muhammad Saddiq
    Ma, Binyun
    Liu, Ren
    Renuse, Santosh
    Sahasrabuddhe, Nandini A.
    Chen, Lily
    Chaerkady, Raghothama
    Kim, Min-Sik
    Zhong, Jun
    Jelinek, Christine
    Barbhuiya, Mustafa A.
    Leal-Rojas, Pamela
    Yang, Yi
    Kashyap, Manoj Kumar
    Marimuthu, Arivusudar
    Ling, Min
    Fackler, Mary Jo
    Merino, Vanessa
    Zhang, Zhen
    Zahnow, Cynthia A.
    Gabrielson, Edward
    Stearns, Vered
    Carlos Roa, Juan
    Sukumar, Saraswati
    Gill, Parkash S.
    Pandey, Akhilesh
    [J]. ONCOTARGET, 2015, 6 (30) : 29143 - 29160
  • [45] Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
    Becker, Kevin
    Xu, Yiqing
    [J]. WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (04): : 560 - 567
  • [46] Acquired cancer tyrosine kinase inhibitor resistance: ROS as critical determinants
    Sander Bekeschus
    [J]. Signal Transduction and Targeted Therapy, 6
  • [47] Tyrosine kinase inhibitor resistance in cancer:: role of ABC multidrug transporters
    Özvegy-Laczka, C
    Cserepes, J
    Elkind, NB
    Sarkadi, B
    [J]. DRUG RESISTANCE UPDATES, 2005, 8 (1-2) : 15 - 26
  • [48] Acquired cancer tyrosine kinase inhibitor resistance: ROS as critical determinants
    Bekeschus, Sander
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2021, 6 (01)
  • [49] Checkpoint inhibitor therapy for metastatic triple-negative breast cancer
    Heeke, Arielle L.
    Tan, Antoinette R.
    [J]. CANCER AND METASTASIS REVIEWS, 2021, 40 (02) : 537 - 547
  • [50] Triple negative breast cancer: current understanding of biology and treatment options
    Kang, Soonmo Peter
    Martel, Maritza
    Harris, Lyndsay N.
    [J]. CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2008, 20 (01) : 40 - 46
12345